CN110637036A - 具有针对可溶性蛋白质的亲和性物质、切割性部分及反应性基团的化合物或其盐 - Google Patents

具有针对可溶性蛋白质的亲和性物质、切割性部分及反应性基团的化合物或其盐 Download PDF

Info

Publication number
CN110637036A
CN110637036A CN201880027775.4A CN201880027775A CN110637036A CN 110637036 A CN110637036 A CN 110637036A CN 201880027775 A CN201880027775 A CN 201880027775A CN 110637036 A CN110637036 A CN 110637036A
Authority
CN
China
Prior art keywords
soluble protein
residue
group
formula
residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880027775.4A
Other languages
English (en)
Chinese (zh)
Inventor
山田慧
松田丰
藤井友博
敷田奈都纪
汤地玲子
新保和高
伊东祐二
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63918939&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN110637036(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Publication of CN110637036A publication Critical patent/CN110637036A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201880027775.4A 2017-04-28 2018-04-27 具有针对可溶性蛋白质的亲和性物质、切割性部分及反应性基团的化合物或其盐 Pending CN110637036A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017090679 2017-04-28
JP2017-090679 2017-04-28
PCT/JP2018/017345 WO2018199337A1 (ja) 2017-04-28 2018-04-27 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩

Publications (1)

Publication Number Publication Date
CN110637036A true CN110637036A (zh) 2019-12-31

Family

ID=63918939

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880027775.4A Pending CN110637036A (zh) 2017-04-28 2018-04-27 具有针对可溶性蛋白质的亲和性物质、切割性部分及反应性基团的化合物或其盐

Country Status (8)

Country Link
US (2) US12024549B2 (https=)
EP (2) EP3617235B1 (https=)
JP (4) JP7222347B2 (https=)
KR (3) KR20240111015A (https=)
CN (1) CN110637036A (https=)
AU (2) AU2018259856B2 (https=)
CA (1) CA3061467A1 (https=)
WO (1) WO2018199337A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112261954A (zh) * 2018-06-14 2021-01-22 味之素株式会社 具有针对抗体的亲和性物质和生物正交性官能团的化合物或其盐
CN112262152A (zh) * 2018-06-14 2021-01-22 味之素株式会社 具有针对抗体的亲和性物质、切割性部分及反应性基团的化合物或其盐
WO2023179723A1 (zh) * 2022-03-25 2023-09-28 中国科学院上海药物研究所 亲和片段导向的可裂解片段，其设计、合成及在制备定点药物偶联物中的应用

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11472865B2 (en) * 2017-06-16 2022-10-18 Kagoshima University IgG-binding peptide, and specific modification of antibody with said peptide
JPWO2020090979A1 (ja) * 2018-10-31 2021-09-24 味の素株式会社 抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
AU2020210506B2 (en) 2019-01-23 2025-02-13 AbTis Co., Ltd. Compound for preparation of antibody-payload conjugate and use thereof
JP7393810B2 (ja) 2019-03-08 2023-12-07 アブティス・カンパニー・リミテッド 部位特異的抗体コンジュゲーション及びその具体例としての抗体－薬物コンジュゲート
WO2021080008A1 (ja) 2019-10-24 2021-04-29 国立大学法人 鹿児島大学 １価ｃｃａｐ生成物の製造方法
JP2023501720A (ja) * 2019-11-18 2023-01-18 クレオ ファーマシューティカルズ， インコーポレイテッド 指向性コンジュゲーション技術
IL293375A (en) 2019-12-03 2022-07-01 Debiopharm Res & Manufacturing S A reactive couplings
WO2022078566A1 (en) 2020-10-12 2022-04-21 Debiopharm Research & Manufacturing S.A. Reactive conjugates
CA3208296A1 (en) * 2021-01-18 2022-07-21 Ajinomoto Co., Inc. Compound or salt thereof, and antibody obtained by using the same
EP4279502A4 (en) 2021-01-18 2026-02-11 Ajinomoto Kk COMPOUND OR ITS SALT, AND ANTIBODIES THUS OBTAINED
EP4306535A1 (en) * 2021-03-11 2024-01-17 Ajinomoto Co., Inc. Compound or salt thereof, and antibody obtained using same
WO2022196675A1 (ja) 2021-03-16 2022-09-22 味の素株式会社 複合体またはその塩、およびその製造方法
CN113292633B (zh) * 2021-05-13 2023-08-29 中国科学技术大学 可见光诱导甘氨酸衍生物的肼化修饰方法
US20240252674A1 (en) * 2021-05-17 2024-08-01 Biohaven Therapeutics Ltd. Agents for directed conjugation techniques and conjugated products
CA3219550A1 (en) * 2021-05-19 2022-11-24 Gene M. Dubowchik Antibody drug conjugates using mates technology for delivering cytotoxic agents
AU2022286137A1 (en) 2021-06-01 2023-12-14 Ajinomoto Co., Inc. Conjugate of antibody and functional substance or salt of said conjugate, and compound for use in production of said conjugate or salt of said compound
US20230201365A1 (en) 2021-07-09 2023-06-29 Bright Peak Therapeutics Ag Modified cd20 antibodies and uses thereof
US20230201364A1 (en) 2021-07-09 2023-06-29 Bright Peak Therapeutics Ag Antibody conjugates and manufacture thereof
WO2023281479A1 (en) 2021-07-09 2023-01-12 Bright Peak Therapeutics Ag Checkpoint inhibitors conjugated to il-2, and uses thereof
WO2023281485A1 (en) 2021-07-09 2023-01-12 Bright Peak Therapeutics Ag Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases
US20230181754A1 (en) 2021-07-09 2023-06-15 Bright Peak Therapeutics Ag Modified checkpoint inhibitors and uses thereof
AU2022342928A1 (en) 2021-09-08 2024-03-28 Kagoshima University Compound, salt of compound, antibody modification reagent, method for producing modified antibody, and modified antibody
KR20240073035A (ko) 2021-09-30 2024-05-24 아지노모토 가부시키가이샤 항체 및 기능성 물질의 컨쥬게이트 또는 그 염, 및 그 제조에 사용되는 항체 유도체 및 화합물 또는 그 염
AU2022353331A1 (en) 2021-09-30 2024-04-11 Ajinomoto Co., Inc. Regioselective conjugate of functional substance and antibody or salt of said conjugate, and antibody derivative and compound for use in production of said conjugate, or salt of said antibody derivative and compound
JP2025508823A (ja) 2022-02-23 2025-04-10 ブライト ピーク セラピューティクス エージー 免疫抗原特異的ｉｌ－１８免疫サイトカイン及びその使用
EP4488290A1 (en) 2022-03-04 2025-01-08 ABTIS Co., Ltd. Method for increasing production yield of antibody-drug conjugate by using thiol-reactive additive
WO2023234416A1 (ja) 2022-06-02 2023-12-07 味の素株式会社 親和性物質、化合物、抗体およびそれらの塩
WO2024096564A1 (ko) 2022-11-01 2024-05-10 앱티스 주식회사 항-클라우딘18.2 항체를 포함하는 항체-약물 컨쥬게이트 및 이의 암에 대한 치료용도
US20240417436A1 (en) 2023-01-11 2024-12-19 Bright Peak Therapeutics Ag Conditionally activated immunocytokines and methods of use
US20240424127A1 (en) 2023-01-11 2024-12-26 Bright Peak Therapeutics Ag Il-7 polypeptides, immunocytokines comprising same, and uses thereof
JPWO2024190896A1 (https=) * 2023-03-15 2024-09-19
JPWO2024210154A1 (https=) 2023-04-04 2024-10-10
KR20250167673A (ko) 2023-04-05 2025-12-01 아지노모토 가부시키가이샤 항체 및 기능성 물질의 컨쥬게이트 또는 그 염, 및 티올기를 갖는 항체 중간체 또는 그 염
WO2025041102A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Targeted immune activation with il-18 immunocytokines
US20250188166A1 (en) 2023-08-23 2025-06-12 Bright Peak Therapeutics Ag Il-18 polypeptides fused to immune cell antigen specific binding polypeptides and uses thereof
WO2025041101A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Activatable il-18 immunocytokines and uses thereof
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025096878A1 (en) 2023-11-02 2025-05-08 Capstan Therapeutics, Inc. Rna for in vivo transfection with increased expression
WO2025129201A1 (en) 2023-12-15 2025-06-19 Capstan Therapeutics, Inc. Humanized anti-cd8 antibodies and uses thereof
WO2025158412A1 (en) 2024-01-26 2025-07-31 Biohaven Therapeutics Ltd. BIFUNCTIONAL DEGRADERS OF IgG4 IMMUNOGLOBULINS
WO2025179294A2 (en) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025181697A1 (en) 2024-02-26 2025-09-04 Biohaven Therapeutics Ltd. Bifunctional degraders of anti-pla2r antibody
WO2025210538A1 (en) 2024-04-02 2025-10-09 Biohaven Therapeutics Ltd. Bifunctional degraders
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2026028158A1 (en) 2024-07-31 2026-02-05 Biohaven Therapeutics Ltd. Targeted degradation of anti-aav antibodies to enable aav-based gene therapy
WO2026028159A1 (en) 2024-07-31 2026-02-05 Biohaven Therapeutics Ltd. Bifunctional degraders for the treatment of graves' disease
KR20260026725A (ko) 2024-08-20 2026-02-27 주식회사 엘지에너지솔루션 배터리의 전극 탭 검사 장치 및 방법
WO2026058917A1 (ja) * 2024-09-10 2026-03-19 味の素株式会社 抗体親和性物質を含む化合物、修飾抗体およびそれらの塩ならびに抗体誘導体または抗体－機能性物質コンジュゲートの製造方法
WO2026069134A1 (en) 2024-09-26 2026-04-02 Bright Peak Therapeutics Ag Human therapy with il-18 immunocytokines

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09327288A (ja) * 1996-06-11 1997-12-22 Nof Corp 修飾蛋白質の製造法及びコンタクトレンズ用汚れ除去剤
EP1056474B1 (en) * 1997-11-07 2002-06-12 ConjuChem, Inc. Affinity markers for human serum albumin
WO2015191883A1 (en) * 2014-06-12 2015-12-17 Dophen Biomedical Homogenous antibody drug conjugates via enzymatic methods
CN105377307A (zh) * 2013-06-24 2016-03-02 韩华石油化学株式会社 具有改进的稳定性的抗体-药物缀合物及其用途
WO2016186206A1 (ja) * 2015-05-20 2016-11-24 国立大学法人鹿児島大学 ＩｇＧ結合ペプチドによる抗体の特異的修飾

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Acylhydrazone derivatives of anthracycline and methods for their preparation
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
ATE234635T1 (de) 1995-12-22 2003-04-15 Bristol Myers Squibb Co Verzweigte hydrazongruppen enthaltende kuppler
EP2180054A1 (en) 1999-12-24 2010-04-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
EP1757311B1 (en) 1999-12-24 2009-02-11 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
DE10162773A1 (de) 2001-12-20 2003-07-10 Knf Flodos Ag Sursee Dosierpumpe
SI1545613T1 (sl) 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
JP2006507322A (ja) 2002-11-14 2006-03-02 シンタルガ・ビーブイ 多重自己脱離放出スペーサーとして構築されたプロドラッグ
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
JP4806680B2 (ja) 2004-05-19 2011-11-02 メダレックス インコーポレイテッド 自己犠牲リンカー及び薬剤複合体
WO2006094269A2 (en) 2005-03-03 2006-09-08 Covx Technologies Ireland Limited Anti-angiogenic compounds
US8637656B2 (en) 2005-07-05 2014-01-28 Ribomic Inc. Nucleic acid capable of binding to immunoglobulin G and use thereof
WO2007099289A1 (en) 2006-02-28 2007-09-07 Medical Research Council Targeted iron oxide nanoparticles
EP2093287A4 (en) 2006-11-02 2010-04-21 Univ Kagoshima PEPTIDE BINDER IGG
EP2089425B1 (en) 2006-11-10 2011-08-17 CovX Technologies Ireland Limited Anti-angiogenic compounds
CA2794631A1 (en) * 2010-03-31 2011-10-06 Universite De Geneve Stabilized antibody preparations and uses thereof
CN103890174B9 (zh) 2011-08-24 2026-04-03 大塚化学株式会社 IgG结合性肽及利用其检测和纯化IgG的方法
WO2014004639A1 (en) 2012-06-26 2014-01-03 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
US20160000933A1 (en) * 2014-07-01 2016-01-07 Andrei POLUKHTIN Conjugated biological molecules and their preparation
JP5827769B1 (ja) 2015-03-27 2015-12-02 義徳 川窪 掃除装置
TWI703158B (zh) * 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
US11135304B2 (en) 2015-12-18 2021-10-05 Eisai R&D Management Co., Ltd. C-terminal lysine conjugated immunoglobulins
JP7020403B2 (ja) * 2016-05-02 2022-02-16 味の素株式会社 アジド基含有Ｆｃタンパク質
SG10202012408UA (en) * 2016-06-13 2021-01-28 Univ Kagoshima SITE-SPECIFIC RADIOISOTOPE-LABELED ANTIBODY USING IgG-BINDING PEPTIDE

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09327288A (ja) * 1996-06-11 1997-12-22 Nof Corp 修飾蛋白質の製造法及びコンタクトレンズ用汚れ除去剤
EP1056474B1 (en) * 1997-11-07 2002-06-12 ConjuChem, Inc. Affinity markers for human serum albumin
CN105377307A (zh) * 2013-06-24 2016-03-02 韩华石油化学株式会社 具有改进的稳定性的抗体-药物缀合物及其用途
WO2015191883A1 (en) * 2014-06-12 2015-12-17 Dophen Biomedical Homogenous antibody drug conjugates via enzymatic methods
WO2016186206A1 (ja) * 2015-05-20 2016-11-24 国立大学法人鹿児島大学 ＩｇＧ結合ペプチドによる抗体の特異的修飾

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ERIK S. ZIMMERMAN等: "Production of Site-Specific Antibody-Drug Conjugates Using Optimized Non-Natural Amino Acids in a Cell-Free Expression System", 《BIOCONJUGATE CHEMISTRY》 *
ERIK S. ZIMMERMAN等: "Production of Site-Specific Antibody-Drug Conjugates Using Optimized Non-Natural Amino Acids in a Cell-Free Expression System", 《BIOCONJUGATE CHEMISTRY》, vol. 25, no. 2, 17 January 2014 (2014-01-17), pages 1 - 11, XP055107336, DOI: 10.1021/bc400490z *
HAYASHI, T.等: "Traceless affinity labeling of endogenous proteins for fuctional analysis in living cells", ACCOUNTS OF CHEMICAL RESEARCH, vol. 45, no. 9, 31 December 2012 (2012-12-31), pages 1460 - 1469 *
HOUZONG YAO等: "Methods to Design and Synthesize Antibody-Drug Conjugates (ADCs)", 《INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES》 *
HOUZONG YAO等: "Methods to Design and Synthesize Antibody-Drug Conjugates (ADCs)", 《INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES》, vol. 17, no. 2, 2 February 2016 (2016-02-02), pages 1 - 16, XP055416120, DOI: 10.3390/ijms17020194 *
KYOJI TSUCHIKAMA等: "Antibody-drug conjugates: recent advances in conjugation and linker chemistries", 《PROTEIN & CELL》 *
KYOJI TSUCHIKAMA等: "Antibody-drug conjugates: recent advances in conjugation and linker chemistries", 《PROTEIN & CELL》, vol. 9, no. 1, 14 October 2016 (2016-10-14), pages 1 - 14 *
高冰;欧瑜;: "蛋白质药物的聚乙二醇定点修饰", 药物生物技术, no. 03, pages 61 - 65 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112261954A (zh) * 2018-06-14 2021-01-22 味之素株式会社 具有针对抗体的亲和性物质和生物正交性官能团的化合物或其盐
CN112262152A (zh) * 2018-06-14 2021-01-22 味之素株式会社 具有针对抗体的亲和性物质、切割性部分及反应性基团的化合物或其盐
CN112261954B (zh) * 2018-06-14 2025-06-24 味之素株式会社 具有针对抗体的亲和性物质和生物正交性官能团的化合物或其盐
WO2023179723A1 (zh) * 2022-03-25 2023-09-28 中国科学院上海药物研究所 亲和片段导向的可裂解片段，其设计、合成及在制备定点药物偶联物中的应用

Also Published As

Publication number Publication date
CA3061467A1 (en) 2019-10-24
EP3617235A1 (en) 2020-03-04
AU2018259856A2 (en) 2019-11-28
JP2025185050A (ja) 2025-12-18
JP7754361B2 (ja) 2025-10-15
JP2023052910A (ja) 2023-04-12
KR20200002858A (ko) 2020-01-08
JP7708133B2 (ja) 2025-07-15
EP3617235A4 (en) 2020-12-16
US20200190165A1 (en) 2020-06-18
AU2018259856A1 (en) 2019-11-14
AU2018259856B2 (en) 2025-05-01
KR20240046307A (ko) 2024-04-08
US20240366783A1 (en) 2024-11-07
KR20240111015A (ko) 2024-07-16
JPWO2018199337A1 (ja) 2020-03-12
JP2025133878A (ja) 2025-09-11
AU2025206404A1 (en) 2025-08-28
US12024549B2 (en) 2024-07-02
EP4603507A3 (en) 2025-10-29
WO2018199337A1 (ja) 2018-11-01
EP4603507A2 (en) 2025-08-20
EP3617235B1 (en) 2026-02-18
JP7222347B2 (ja) 2023-02-15

Similar Documents

Publication Publication Date Title
JP7754361B2 (ja) 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
US12428450B2 (en) Compound having affinity substance to antibody, cleavable portion, and reactive group, or salt thereof
KR102880460B1 (ko) 항체에 대한 친화성 물질 및 생체 직교성 관능기를 갖는 화합물 또는 이의 염
KR102921757B1 (ko) 항체에 대한 친화성 물질, 절단성 부분 및 반응성기를 갖는 화합물 또는 이의 염
US20240058473A1 (en) Complex or salt thereof, and method for producing the same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination